HIGH RISK STANDARD RISK LOW RISK

### \*\*CAUTION\*\*

Patient at risk for THROMBOTIC EVENTS may require consultation for bridging anticoagulation therapy (eg. PROSTHETIC HEART VALVES, VENOUS THROMBOEMBOLISM, ATRIAL FIBRILLATION WITH PRIOR STROKE)

Premature discontinuation of anti-platelet drugs in patients with CORONARY STENTS may precipitate acute stent thrombosis

Do not stop anticoagulation in these patients without consultation

HIGH RISK PROCEDURES							
HIGH RISK  INR ≤ 1.3 Platelets > 80 x 10 <sup>9</sup> /L Inpatients 72 hours Outpatients 2 weeks	Anticoagulant / Antiplatelet MEDS	Discontinue Yes*/ No	Timing of LAST dose BEFORE procedure*	Timing of FIRST dose AFTER day of procedure*			
VASCULAR	aspirin (ASA), low dose (81 mg)	No					
<ul><li>TIPS</li><li>Arterial interventions &gt;7Fr access</li></ul>	<ul><li>clopidogrel (Plavix®)</li><li>aspirin, non-low dose</li><li>ticagrelor (Brilinta®)</li></ul>	Yes	- 8 days	Day + 1 or + 2			
NON-VASCULAR	<ul><li>prasurgrel (Effient®)</li></ul>	Yes	- 8 days	Day + 1 or + 2			
Abdominal Procedures  Renal core biopsy PCNL/Nephrostomy Biliary drainage (PTBD) Complex thermal ablation – liver, kidney, lung, MSK  NOTE: Specialized Neurovascular Procedures are excluded, including carotid stenting, and intra-cranial embolization	<ul> <li>NSAIDs</li> </ul>	Yes	- 4 days	Day + 1			
	<ul><li>warfarin (Coumadin®)</li></ul>	Yes	- 6 days CHECK INR 24 hrs prior	Day + 1			
	<ul> <li>subcutaneous heparin (prophylactic)</li> </ul>	Yes	- 8 hrs prior	Day 0 (evening)			
	<ul><li>low molecular weight heparin (LMWH)</li></ul>	Yes	prophylactic: > 12 hrs prior therapeutic: > 24 hrs prior	Day + 1 Day + 2 or + 3			
	<ul><li>(IV) unfractionated heparin</li><li>REQUIRES PTT</li></ul>	Yes	infusion to stop 4 hrs prior (goal: PTT ≤ 43 s)	12 hrs after			
	■ dabigatran (Pradaxa®)	Yes	GFR >50: - 3 days GFR ≤50: - 5 days	Day + 2 or + 3			
	<ul><li>rivaroxaban (Xarelto®)</li><li>apixaban (Eliquis®)</li></ul>	Yes	- 3 days	Day + 2 or + 3			
	■ fondaparinux (Arixtra®)	Yes	prophylactic: > 24 hrs therapeutic: > 48 hrs	Day + 1 Day + 2 or + 3			

\*Ordering Physician must give instructions to patient









# Management Guidelines for Patients Having \* ELECTIVE \* Invasive Procedures in Medical Imaging

STANDARD RISK PROCEDURES						
STANDARD RISK  INR ≤ 1.5 Platelets > 50 x 10°/L Inpatients 72 hours Outpatients 30 days	Anticoagulant / Antiplatelet MEDS	Discontinue *Yes/ No	Timing of LAST dose BEFORE procedure*	Timing of FIRST dose AFTER Day of procedure*		
VASCULAR  Angiography/arterial intervention up to 7 Fr access, including diagnostic neuroangiography Central venous interventions Uterine fibroid embolization Transjugular liver biopsy Tunneled CVC/Port/Hickman  NON-VASCULAR  Abdominal/Thoracic Procedures Intraabdominal, chest wall, pleural or retroperitoneal abscess drainage, core biopsy Diagnostic or therapeutic thoracentesis or paracentesis Gastrostomy/gastrojejunostomy Percutaneous cholecystostomy Lithotripsy (ESWL/ISWL) Lung biopsy Uncomplicated thermal ablation — liver, kidney, MSK, lung Core biopsy - prostate Transabdominal liver biopsy Fallopian tube recanalization	<ul> <li>aspirin (ASA), any dose</li> </ul>	No		Day + 1		
	<ul><li>clopidogrel (Plavix®)</li><li>ticagrelor (Brilinta®)</li></ul>	Yes	- 6 days	Day + 1		
	<ul><li>prasurgrel (Effient®)</li></ul>	Yes	- 8 days	Day + 1		
	<ul><li>warfarin (Coumadin®)</li></ul>	Yes	- 6 days CHECK INR 24 hrs prior	Day 0 (evening)		
	<ul><li>subcutaneous heparin (prophylactic)</li></ul>	Yes	- 8 hrs prior	Day 0 (evening)		
	<ul> <li>low molecular weight heparin (LMWH)</li> </ul>	Yes	prophylactic: > 12 hrs therapeutic: > 24 hrs	Day + 1		
	<ul><li>(IV) unfractionated heparin</li><li>REQUIRES PTT</li></ul>	Yes	Infusion to stop 4 hours prior (goal: PTT ≤ 50 s)	6 hrs after		
	■ dabigatran (Pradaxa®)	Yes	GFR >50: - 2 days GFR ≤50: - 3 days	Day + 2		
<ul> <li>MSK/Spine Procedures</li> <li>Lumbar puncture, epidural injection, facet block, rhizotomy, nerve root block</li> <li>Vertebroplasty/kyphoplasty</li> <li>Spine biopsy, paraspinal injection</li> <li>Extremity/MSK core biopsy</li> </ul>	<ul><li>rivaroxaban (Xarelto®)</li><li>apixaban (Eliquis®)</li></ul>	Yes	- 2 days	Day + 2		
	■ fondaparinux (Arixtra®)	Yes	prophylactic: > 24 hrs therapeutic: > 48 hrs	Day + 1 Day + 2		

\*Ordering Physician must give instructions to patient









## Management Guidelines for Patients Having \* E L E C T I V E \* Invasive Procedures in Medical Imaging

LOW RISK PROCEDURES							
LOW RISK  Confirm INR ≤ 2.0 if known or suspected liver disease	Anticoagulant / Antiplatelet MEDS	Discontinue Yes*/ No	Timing of LAST dose BEFORE procedure if discontinuing	Timing of FIRST dose AFTER day of procedure*			
<ul> <li>VASCULAR</li> <li>Dialysis access or peripheral venous interventions, including varicocele embolization</li> <li>IVC filter placement/removal</li> <li>PICC insertion</li> <li>Uncomplicated catheter/line exchange/removal</li> <li>Diagnostic venography</li> </ul>	<ul> <li>aspirin (ASA), any dose</li> </ul>	No					
	<ul><li>clopidogrel (Plavix®)</li><li>ticagrelor (Brilinta®)</li></ul>	Possible to continue	- 6 days	Day + 1			
	■ prasurgrel (Effient®)	Possible to continue	- 8 days	Day + 1			
NON-VASCULAR  Catheter exchange or removal (GU, biliary, abscess) Superficial abscess drainage Core biopsy - breast Peripheral joint injection or aspiration GI tract stenting (colon, esophagus) Hysterosalpingography	<ul><li>warfarin (Coumadin®)</li><li>RECOMMEND INR ≤ 2.0</li></ul>	Possible to continue	- 4 days CHECK INR 24 hrs prior	Day 0 (evening)			
	<ul><li>subcutaneous heparin</li><li>low molecular weight heparin (LMWH) – prophylactic</li></ul>	No					
	<ul> <li>low molecular weight heparin (LMWH) – therapeutic</li> </ul>	Possible to continue	> 24 hrs	Day + 1			
Superficial Aspiration / Biopsy (FNAB)  Breast Extremities Lymph nodes Thyroid  NOTE: Most LOW risk procedures do not require the discontinuation of anticoagulation/antiplatelet therapy.	<ul> <li>(IV) unfractionated heparin</li> </ul>	Possible to continue	Infusion to stop 4 hrs prior	4 hrs			
	■ dabigatran (Pradaxa®)	Possible to continue	GFR >50: - 2 days GFR ≤50: - 3 days	Day + 1			
	<ul><li>rivaroxaban (Xarelto®)</li><li>apixaban (Eliquis®)</li></ul>	Possible to continue	- 2 days	Day + 1			
	■ fondaparinux (Arixtra®)	Possible to continue	prophylactic: > 24 hrs therapeutic: > 48 hrs	Day + 1			

\*Ordering Physician must give instructions to patient









### Management Guidelines for Patients Having \* E L E C T I V E \* Invasive Procedures in Medical Imaging

## **Booking Clerk Script:**

- "You are booked for a: \_\_\_\_\_\_ procedure in Medical Imaging.
  If you are on any blood thinner medication, you <u>must</u> ask your Ordering Physician for instructions on discontinuing and resuming your medications".
- We ask that you contact your doctor for more details on this, as we have faxed this info to them.
- If you don't discuss this with your doctor, your procedure may be cancelled.

### Please Note:

- Patients on anti-inflammatory medications (NSAIDs) such as the following: (Advil® [ibuprofen], Voltaren®,
   Celebrex®) may continue taking them, except for HIGH RISK procedures.
- Please inform your Ordering Physician if you are taking supplements as these may affect blood test results.

### References

- 1. SIR Journal of Vascular Radiology 2009; 20:S240-S249 Consensus Guidelines for Periprocedural management of Coagulation Status and Hemostasis Risk in Percutaneous Image-guided Interventions
- 2. Canadian Journal of Cardiology 2011; 27:S1-S59 The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines
- 3. Department of Hematology, VCHA, 27 Jan 2015 Recommendations for the Interruption of Anticoagulation or Anti-platelet Therapy for Elective Invasive Procedures or Surgery

#### External links to online version

http://www.vch.ca/403/7676/?program\_id=2148

http://www.fraserhealth.ca/find\_us/services/our\_services?program\_id=8647

### Intranet links to online version

http://vhnet/programs\_services/diagnostic\_imaging/medical\_imaging\_modalities/angiography/page\_33891.htm http://fhpulse/clinical\_support\_services/mi\_and\_nm/Pages/RegionalGuidelines.aspx

Version 10.2 effective 30 March 2015







